Because impaired lipid metabolism leads to obesity and related metabolic diseases, such as dyslipidemia, atherosclerosis, type 2 diabetes, and nonalcoholic fatty liver disease (NAFLD) [10,11,12], improved PPARα activity is required to prevent or treat this group of disorders. Here, PPARA is linked to obesity due to melanocortin 4 receptor deficiency.